CYC-065
CYC-065 Basic information
- Product Name:
- CYC-065
- Synonyms:
-
- CYC065; CYC-065; CYC 065;1070790-89-4
- CDK259
- CYC065 base
- CPD1574
- CYC065, CDK259
- CYC065 free base
- 2-Pentanol, 3-[[6-[[(4,6-dimethyl-3-pyridinyl)methyl]amino]-9-(1-methylethyl)-9H-purin-2-yl]amino]-, (2R,3S)-
- Fadraciclib（CYC065）
- CAS:
- 1070790-89-4
- MF:
- C21H31N7O
- MW:
- 397.52
- Product Categories:
-
- api
- Mol File:
- 1070790-89-4.mol
CYC-065 Chemical Properties
- Boiling point:
- 618.3±65.0 °C(Predicted)
- Density
- 1.25±0.1 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- DMSO:100.0(Max Conc. mg/mL);251.55(Max Conc. mM)
- form
- A solid
- pka
- 14.62±0.20(Predicted)
- color
- White to off-white
CYC-065 Usage And Synthesis
Uses
Fadraciclib (CYC065) is a second-generation, orally available ATP-competitive inhibitor of CDK2/CDK9 kinases[1] with IC50s of 5 and 26 nM, respectively[2].
in vivo
To evaluate the therapeutic potential of Fadraciclib as a single agent, USC-ARK-2-derived xenografts are treated daily with Fadraciclib (22.5 mg/kg) for a 3-week period. Tumor size and mouse weight are recorded two times a week. The daily administration of Fadraciclib results in a significant reduction of tumor growth compared with the vehicle-treated mice (P=0.012 starting at day 9 of the treatment). No significant weight loss is reported during the entire treatment period[1].
IC 50
CDK2; CDK9
References
[1] Cocco E, et al. Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo. Br J Cancer. 2016 Jul 26;115(3):303-11. DOI:10.1038/bjc.2016.198
[2] Sumana Devata, et al. Molecular markers and venous thromboembolism (VTE) in acute myelogenous leukemia (AML)
CYC-065Supplier
- Tel
- 021-58955995
- sales@medchemexpress.cn
- Tel
- 18149758185
- sales-cpd@caerulumpharma.com
- Tel
- 19916721580
- mafarm@126.com
- Tel
- 021-52996696，15000506266 15000506266
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com